Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Rhea-AI Summary

Arbutus Biopharma Corporation (ABUS) announced the schedule for its Q4 and year-end 2023 financial results and corporate update, set for February 29, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection leveraging its virology expertise.

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows:

•	Q4 and Year End 2023 Press Release:	Thursday, February 29, 2024 at 7:30 a.m. ET
•	Q4 and Year End 2023 Conference Call/Webcast:	Thursday, February 29, 2024 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When is Arbutus Biopharma Corporation (ABUS) releasing its Q4 and Year End 2023 financial results?

Arbutus Biopharma Corporation (ABUS) is releasing its Q4 and Year End 2023 financial results on Thursday, February 29, 2024 at 7:30 a.m. ET.

What time is the conference call/webcast for Arbutus Biopharma Corporation (ABUS) scheduled on February 29, 2024?

The conference call/webcast for Arbutus Biopharma Corporation (ABUS) is scheduled on February 29, 2024, at 8:45 a.m. ET.

Where can I access the live webcast of the conference call for Arbutus Biopharma Corporation (ABUS)?

The live webcast of the conference call for Arbutus Biopharma Corporation (ABUS) can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.